Saturday 17 October 2026
Export HSCS’s income statement to Excel — free account
HeartSciences Inc.
HSCS Healthcare Medical Devices
HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025. In the quarter to July 2026, revenue fell 46.2%, EPS grew 45.6% and free cash flow grew 18.2%, each against the same quarter a year earlier.
3.02
0.16
−5.03%
Follow HSCS
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | 0.00 |
P/S ratio |
370.33 | — | — | 379.06 | |
P/FCF ratio |
0.00 | — | — | 0.00 | |
P/Operating CF |
(3.63) | — | — | (6.06) | |
P/B ratio |
2.03 | — | — | 0.00 | |
Price to Tangible BV |
3.32 | — | — | 0.00 | |
EV/Sales |
298.21 | — | — | 409.47 | |
EV/EBITDA |
0.00 | — | — | 0.00 | |
EV/Operating CF |
(0.91) | — | — | (1.27) | |
EV/FCF |
(0.91) | — | — | (1.21) | |
Quick Ratio |
1.25 | 0.80 | 0.34 | 0.01 | |
Current Ratio |
2.42 | 1.19 | 0.53 | 0.14 | |
Net Debt/EBITDA |
1.10 | 1.59 | 0.69 | 0.01 | |
Debt/Assets |
0.00% | 5.58% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.16 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.99 | 0.74 | 0.61 | 0.42 | |
Capex/Depreciation |
(0.05) | (0.51) | 0.00 | (2.07) | |
Interest Coverage |
(7.42) | (31.36) | (11.11) | (12.49) | |
Research and Development Expense of Revenue |
30,291.67% | 0.00% | 0.00% | 43,171.43% | |
Selling, General and Administrative Expense of Revenue |
56,158.33% | 0.00% | 0.00% | 96,847.62% | |
Intangible Assets out of Total Assets |
0.27 | 0.22 | 0.31 | 0.44 | |
Share Based Compensation of Revenue |
18,200.00% | 0.00% | 0.00% | 35,185.71% | |
Graham Net Nets |
0.23 | — | — | (0.62) | |
Graham Number |
0.00 | — | — | 6.34 | |
Earnings Yield |
(225.57%) | — | — | (147.71%) | |
Free Cash Flow Yield |
(88.93%) | — | — | (88.97%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.84) | (0.46) | (0.64) | (0.36) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.08) | |
Free Cash Flow per Share |
(0.85) | (0.47) | (0.64) | (0.44) | |
Cash per Share |
0.70 | 1.07 | 0.63 | 0.01 | |
Shareholders Equity per Share |
1.50 | 0.84 | 0.09 | (0.55) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.50 | 0.84 | 0.09 | (0.55) | |
Free Cash Flow |
(2.35) | (1.49) | (1.68) | (1.60) | |
Working Capital |
2.23 | 0.83 | (2.28) | (4.82) | |
Capital Expenditures |
(0.02) | (0.03) | 0.00 | (0.28) | |
Net Current Asset Value |
1.98 | 0.20 | (2.45) | (4.96) | |
EV/EBIT |
0.00 | — | — | 0.00 | |
Capex to Sales |
6.58 | 0.00 | 0.00 | 133.38 | |
Price to Operating Income |
0.00 | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
0.30 | 0.41 | 0.32 | 0.65 | |
Average Inventory |
0.66 | 0.65 | 0.65 | 0.53 | |
Average Assets |
6.89 | 6.63 | 4.74 | 5.09 | |
Average Common Equity |
4.10 | 2.22 | 0.22 | 0.55 |
Columns are period end dates · fundamentals updated 1 Oct 2026